Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma
Published on 30 May 2026
Dr Xue-Feng Leng reviews results from the phase III SCIENCE trial with ecancer at ASCO 2026, which showed that neoadjuvant chemoradiotherapy plus sintilimab improved pathological complete response rates in resectable locally advanced oesophageal squamous cell carcinoma.
The discussion also explores the potential of ctDNA clearance as an early biomarker of treatment response.